Log In
Print
BCIQ
Print
Print this Print this
 

ITCA 650

  Manage Alerts
Collapse Summary General Information
Company Intarcia Therapeutics Inc.
DescriptionContinuous subcutaneous delivery of exenatide from implantable Duros device
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Quintiles Transnational Holdings Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today